BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24905321)

  • 1. Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
    Hao GT; Zhou HY; Gao HZ; Qu HY; Liang YG; Li YY; Dong RH; Zhang LJ; Wang XF; Liu ZY
    Pharmacol Rep; 2014 Feb; 66(1):153-8. PubMed ID: 24905321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
    Saari TI; Grönlund J; Hagelberg NM; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2010 Apr; 66(4):387-97. PubMed ID: 20076952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
    Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S
    Nephrol Dial Transplant; 2019 Apr; 34(4):692-702. PubMed ID: 30189012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grapefruit juice enhances the exposure to oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
    Kokki M; Heikkinen M; Välitalo P; Hautajärvi H; Hokkanen J; Pitkänen H; Sankilampi U; Ranta VP; Kokki H
    Br J Clin Pharmacol; 2017 Apr; 83(4):791-800. PubMed ID: 27780305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
    Kirvela M; Lindgren L; Seppala T; Olkkola KT
    J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
    Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
    J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
    Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
    PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
    Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
    Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
    Huang L; Edwards SR; Smith MT
    Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
    Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
    J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.
    Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2010 Oct; 66(10):977-85. PubMed ID: 20697700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
    Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
    Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations.
    Gammaitoni AR; Davis MW
    J Clin Pharmacol; 2002 Feb; 42(2):192-7. PubMed ID: 11831542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.